ADMA BIOLOGICS, INC. (NASDAQ:ADMA) Files An 8-K Regulation FD Disclosure
As previously disclosed, Adam Grossman, President and Chief Executive Officer of ADMA Biologics, Inc., a Delaware corporation (the “Company”), and Brian Lenz, the Company’s Executive Vice President and Chief Financial Officer, plan to present a corporate overview at the 2019 Cantor Global Healthcare Conference in New York City, on Wednesday, October 2, 2019 at 10:40 AM ET (the “Investor Presentation”). The Investor Presentation will be webcast live and may be accessed under the “Investors” tab on the Company’s website at www.admabiologics.com. Additionally, a copy of the slides comprising the Investor Presentation is included as Exhibit 99.1 to this Current Report on Form 8-K.
In accordance with General Instruction B.2 of Form 8-K, the information set forth in this Item 7.01 and the Investor Presentation slides included in this report as Exhibit 99.1 are “furnished” and shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall such information be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act.
Please refer to Exhibit 99.1 for a discussion of certain forward-looking statements included therein and the risks and uncertainties related thereto.
|99.1||ADMA Biologics, Inc. October 2019 Investor Presentation.|
ADMA BIOLOGICS, INC. Exhibit
To view the full exhibit click
About ADMA BIOLOGICS, INC. (NASDAQ:ADMA)
ADMA Biologics, Inc. is a late-stage biopharmaceutical company that develops, manufactures and intends to market specialty plasma-based biologics for the treatment and prevention of infectious diseases. The Company is engaged in the development and commercialization of human plasma and plasma-derived therapeutics. Its segments include Plasma Collection Centers, which includes its operations in Georgia; Research and Development, which includes its plasma development operations in New Jersey, and Corporate. Its targeted patient populations are immune-compromised individuals suffering from an underlying immune deficiency disorder or may be immune-suppressed for medical reasons. Its product candidates are intended to be used by physician specialists focused on caring for immune-compromised patients at risk of contracting infectious diseases. Its intravenous immunoglobulin product candidate, RI-002, is intended for the treatment of primary immune deficiency disease.